{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:22:29Z","timestamp":1790702549841,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ahj.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T05:21:25Z","timestamp":1542864085000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction"],"prefix":"10.1016","volume":"208","author":[{"given":"C. Michael","family":"Gibson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Daaboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Korjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Poyan","family":"Mehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Tricoci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Feaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdi","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton Oude","family":"Ophuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2018.11.008_bb0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.11.008_bb0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","article-title":"Cardiovascular disease risk profiles","volume":"121","author":"Anderson","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.CIR.83.1.356","article-title":"An updated coronary risk profile. A statement for health professionals","volume":"83","author":"Anderson","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.11.008_bb0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2012.01.029","article-title":"The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non\u2013ST-elevation myocardial infarction","volume":"163","author":"Duffy","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0030","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0035","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/eurheartj\/ehi186","article-title":"High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial","volume":"26","author":"Olsson","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2006.04.006","article-title":"Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non\u2013ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation","volume":"98","author":"Wolfram","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0045","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1093\/eurheartj\/ehn364","article-title":"Patterns and prognostic implications of low high-density lipoprotein levels in patients with non\u2013ST-segment elevation acute coronary syndromes","volume":"29","author":"Roe","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0050","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.amjcard.2013.05.050","article-title":"Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-st segment elevation myocardial infarction (from the National Cardiovascular Data Registry)","volume":"112","author":"Acharjee","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0055","first-page":"75","article-title":"High-density lipoproteins and myocardial necrosis in patients with acute myocardial infarction and ST segment elevation","volume":"213","author":"Fabregat-Andres","year":"2013","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.ahj.2018.11.008_bb0060","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0065","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0070","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators TA-H","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0075","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0080","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/HCO.0000000000000211","article-title":"HDL-cholesterol and cardiovascular disease","volume":"30","author":"Siddiqi","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11883-015-0554-1","article-title":"HDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic target","volume":"18","author":"Bhatt","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ahj.2018.11.008_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0095","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurheartj\/ehu105","article-title":"The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of hdl function after an acute coronary syndrome: The dal-ACUTE randomized trial","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11883-009-0009-7","article-title":"High-density lipoprotein\/apolipoprotein a-i infusion therapy","volume":"11","author":"Tardif","year":"2009","journal-title":"Curr Atheroscler Rep"},{"issue":"Suppl. A","key":"10.1016\/j.ahj.2018.11.008_bb0105","first-page":"A31","article-title":"An overview of reverse cholesterol transport","volume":"19","author":"Tall","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1586\/14779072.6.9.1203","article-title":"HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications","volume":"6","author":"Remaley","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ahj.2018.11.008_bb0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0120","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0125","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/ATVBAHA.114.303720","article-title":"CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects","volume":"34","author":"Gille","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0130","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002171","article-title":"Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: Safety and pharmacokinetic results from a phase 2a randomized clinical trial","volume":"4","author":"Tricoci","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2018.11.008_bb0135","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/ATVBAHA.113.301981","article-title":"Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances abca1-dependent cholesterol efflux","volume":"33","author":"Diditchenko","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcph.194","article-title":"A multiple ascending dose study of CSL112, an infused formulation of ApoA-I","volume":"54","author":"Easton","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clinbiochem.2014.09.001","article-title":"Alteration of HDL functionality and pon1 activities in acute coronary syndrome patients","volume":"47","author":"Bounafaa","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ahj.2018.11.008_bb0150","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/CIRCRESAHA.114.303454","article-title":"Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase","volume":"114","author":"Shao","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2018.11.008_bb0155","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/jat.3264","article-title":"Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component","volume":"36","author":"Herzog","year":"2015","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0160","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.11.008_bb0165","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.116.025687","article-title":"Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: The AEGIS-I trial (ApoA-I Event Reducing in Ischemic Syndromes I)","volume":"134","author":"Michael Gibson","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.11.008_bb0170","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.11.008_bb0175","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.ehj.2004.08.016","article-title":"Association of glomerular filtration rate on presentation with subsequent mortality in non\u2013ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials","volume":"25","author":"Gibson","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0180","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0185","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2018.11.008_bb0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ahj.2016.06.017","volume":"180","author":"Gibson","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2018.11.008_bb0195","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.ackd.2014.08.005","article-title":"The management of acute coronary syndromes in patients with chronic kidney disease","volume":"21","author":"Roberts","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ahj.2018.11.008_bb0200","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/CIR.0000000000000183","article-title":"Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association","volume":"131","author":"Washam","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.11.008_bb0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/heartjnl-2017-311975","article-title":"Contrast-induced acute kidney injury and mortality in st elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"104","author":"Silvain","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2018.11.008_bb0210","first-page":"A16500","article-title":"CSL112 restores cholesterol efflux in patients immediately after acute myocardial infarction","volume":"136","author":"Gille","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.11.008_bb0215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yjmcc.2017.05.001","article-title":"Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD","volume":"112","author":"Ganda","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ahj.2018.11.008_bb0220","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/joim.12290","article-title":"Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease","volume":"277","author":"Calabresi","year":"2015","journal-title":"J Intern Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318303247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318303247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:02:00Z","timestamp":1757570520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318303247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":44,"alternative-id":["S0002870318303247"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.11.008","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}